Cynata Therapeutics Limited Stock Buy Hold or Sell Recommendation
| CYYNF Stock | USD 0.19 0.00 0.00% |
Assuming the 90 days horizon and complete risk avoidance on your part, our recommendation regarding Cynata Therapeutics Limited is 'Strong Sell'. Macroaxis provides Cynata Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding CYYNF positions.
Check out Cynata Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Cynata and provide practical buy, sell, or hold advice based on investors' constraints. Cynata Therapeutics Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Cynata |
Execute Cynata Therapeutics Buy or Sell Advice
The Cynata recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Cynata Therapeutics Limited. Macroaxis does not own or have any residual interests in Cynata Therapeutics Limited or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Cynata Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Not Rated
Cynata Therapeutics Trading Alerts and Improvement Suggestions
| Cynata Therapeutics generated a negative expected return over the last 90 days | |
| Cynata Therapeutics has some characteristics of a very speculative penny stock | |
| Cynata Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 7.77 M. Net Loss for the year was (5.45 M) with profit before overhead, payroll, taxes, and interest of 7.77 M. | |
| Cynata Therapeutics Limited has accumulated about 26.79 M in cash with (3.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.19. | |
| Roughly 15.0% of the company shares are held by company insiders |
Cynata Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Cynata Therapeutics or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Cynata Therapeutics' price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Cynata pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.00 | |
β | Beta against Dow Jones | 0.00 | |
σ | Overall volatility | 0.00 | |
Ir | Information ratio | 0.00 |
Cynata Therapeutics Volatility Alert
At this time Cynata Therapeutics Limited exhibits very low volatility. Cynata Therapeutics Limited is a potential penny stock. Although Cynata Therapeutics may be in fact a good instrument to invest, many penny pink sheets are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Cynata Therapeutics Limited. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Cynata instrument if you perfectly time your entry and exit. However, remember that penny pink sheets that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Cynata Therapeutics Fundamentals Vs Peers
Comparing Cynata Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Cynata Therapeutics' direct or indirect competition across all of the common fundamentals between Cynata Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Cynata Therapeutics or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Cynata Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Cynata Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Cynata Therapeutics to competition |
| Fundamentals | Cynata Therapeutics | Peer Average |
| Return On Equity | -0.21 | -0.31 |
| Return On Asset | -0.13 | -0.14 |
| Profit Margin | (0.70) % | (1.27) % |
| Operating Margin | (0.78) % | (5.51) % |
| Current Valuation | 12.47 M | 16.62 B |
| Shares Outstanding | 143.28 M | 571.82 M |
| Shares Owned By Insiders | 14.77 % | 10.09 % |
| Shares Owned By Institutions | 24.80 % | 39.21 % |
| Price To Book | 2.66 X | 9.51 X |
| Price To Sales | 5.53 X | 11.42 X |
| Revenue | 7.77 M | 9.43 B |
| Gross Profit | 7.77 M | 27.38 B |
| EBITDA | (13.56 M) | 3.9 B |
| Net Income | (5.45 M) | 570.98 M |
| Cash And Equivalents | 26.79 M | 2.7 B |
| Cash Per Share | 0.19 X | 5.01 X |
| Current Ratio | 16.25 X | 2.16 X |
| Book Value Per Share | 0.17 X | 1.93 K |
| Cash Flow From Operations | (3.3 M) | 971.22 M |
| Earnings Per Share | (0.02) X | 3.12 X |
| Number Of Employees | 10 | 18.84 K |
| Beta | 0.61 | -0.15 |
| Market Capitalization | 35.82 M | 19.03 B |
| Total Asset | 26.55 M | 29.47 B |
| Net Asset | 26.55 M |
Cynata Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Cynata . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Cynata Therapeutics Buy or Sell Advice
When is the right time to buy or sell Cynata Therapeutics Limited? Buying financial instruments such as Cynata Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Cynata Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Food Products Thematic Idea Now
Food Products
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Food Products theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Food Products Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Cynata Pink Sheet
Cynata Therapeutics financial ratios help investors to determine whether Cynata Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cynata with respect to the benefits of owning Cynata Therapeutics security.